Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028

뉴스 본문을 불러오고 있어요.

Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028 | 웨이프 WAPE

Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028

기사 요약

관련 종목

댓글 —